Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 755-761

  Patel, Pragna ^a   Bush, Tim ^a   Overton, Turner ^b   Baker, Jason ^c   Hammer, John ^d   Kojic, Erna ^e   Conley, Lois ^a   Henry, Keith ^c   Brooks, John T ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Denver Infectious Disease Consultants   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MOLECULAR MARKER; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PADGEM PROTEIN; PROTEINASE INHIBITOR; PROTHROMBIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERUM AMYLOID A; SERUM AMYLOID P; TENOFOVIR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS INHIBITION;

ADENINE; ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RISK FACTORS;

EID: 84861691067     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2020     Document Type: Article

References (24)

1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
2. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-1942. (Pubitemid 29509554)
3. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
4. The D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
5. Palella FJ, Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)
6. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262-270.
7. The D:A:D Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
8. The D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
9. Obel N, Farkas DK, Kronberg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11:130-136.
10. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
11. Bedimo R, Westfall A, Drechsler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract MOAB202.
12. Satchell C, O'Connor EO, Peace A, et al. Platelet hyper-reactivity in HIV-1-infected patients on abacavir-containing ART. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 151LB.
13. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021-2027.
14. The SMART/INSIGHT Study Group, D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
15. Kristoffersen US, Kofoed K, Kronberg G, Benfield T, Kjaer A, Lebech AM. Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. HIV Med 2009; 10:627-633.
16. Martínez E, Larrousse M, Podzamczer D, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-F9.
17. Palella FJ, Gange SJ, Benning L, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24:1657-1665.
18. McComsey G, Smith K, Patel P, et al. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtracitabine: the HEAT Study. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 732.
19. Martin A, Amin J, Cooper DA, et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010; 24:2657-2663.
20. Ding X, Andraca-Carrera E, Cooper C, et al. No association of myocardial infarction with abacavir use: findings of an FDA meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 1004.
21. Vellozzi C, Brooks JT, Bush TJ, et al. The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study). Am J Epidemiol 2009; 169:642-652.
22. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Serum amyloid P and cardiovascular disease in older men and women: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 2007; 27:352-358. (Pubitemid 46143051)
23. Neuhaus J, Jacobs DR, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
24. Saumoy M, Ordonez-Llanos J, Martinez E, et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther 2011; 16:459-468.